Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
InflaRx N.V. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
IFRX
Nasdaq
2830
www.inflarx.de
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for InflaRx N.V.
Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch
- Feb 3rd, 2025 5:07 pm
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
- Jan 23rd, 2025 12:30 pm
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
- Jan 16th, 2025 4:05 pm
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
- Jan 16th, 2025 3:49 pm
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
- Jan 15th, 2025 5:30 pm
InflaRx Announces Participation in January Events in San Francisco
- Jan 7th, 2025 12:30 pm
US Penny Stocks To Watch In December 2024
- Dec 24th, 2024 5:07 pm
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
- Dec 20th, 2024 12:30 pm
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?
- Nov 19th, 2024 11:29 pm
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
- Nov 15th, 2024 12:51 pm
Prenetics Global And 2 Other US Penny Stocks To Watch
- Nov 14th, 2024 12:07 am
InflaRx Reports Q3 2024 Financial Results and Progress
- Nov 13th, 2024 4:00 am
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
- Nov 10th, 2024 1:36 pm
InflaRx expects cash to fund operations into 2026
- Nov 9th, 2024 12:41 pm
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates
- Nov 8th, 2024 1:40 pm
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 8th, 2024 12:30 pm
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
- Oct 31st, 2024 11:30 am
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
- Sep 25th, 2024 11:30 am
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
- Sep 3rd, 2024 11:30 am
InflaRx Announces Participation in September Investor Events
- Aug 27th, 2024 11:30 am
Scroll